EP Patent

EP3599237B1 — Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment of gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient

Assigned to Genzyme Corp · Expires 2021-03-24 · 5y expired

What this patent protects

Patent listed against eliglustat-tartrate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3599237B1
Jurisdiction
EP
Classification
—
Expires
2021-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.